Journal Retracts Amgen’s Tavneos Study, Sparking Regulatory and Investor Concerns
AMGN•The New England Journal of Medicine has retracted the pivotal study on Tavneos (avacopan) following a request by two academic co-authors. Avacopan, Amgen’s treatment for ANCA vasculitis, now faces potential regulatory reviews and investor uncertainty over its clinical data integrity.
1. Retraction Details
The New England Journal of Medicine formally withdrew the pivotal study paper on Tavneos (avacopan) after two academic co-authors identified issues and requested removal. This study had underpinned key efficacy and safety claims in support of regulatory submissions for ANCA vasculitis treatment.
2. Implications for Amgen
With the cornerstone clinical data now retracted, Amgen may encounter renewed regulatory scrutiny of avacopan’s trial design and results. Investors are likely to reassess the drug’s market potential and timeline, raising questions about future revenue projections and development costs.
